ArticleArteriosclerosis, thrombosis, and vascular biology2012
Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Injectable hydrogels for bone regeneration: from materials design to clinical translation.RSC advances · 2026Review
- The Role of Heparan Sulfate in Bone Repair and Regeneration.Calcified tissue international · 2025Review
- Promising Adventitia in Atherosclerosis.Current vascular pharmacology · 2025Review
- The Arteria Lymphatica and Lymphatic Microperforators: A Dedicated Blood Supply to Collecting Lymphatics and Their Potential Implications in Lymphedema: Anatomical Description.Plastic and reconstructive surgery. Global open · 2024Article
- Novel treatment from a botanical formulation Si-Miao-Yong-an decoction inhibits vasa vasorum angiogenesis and stabilizes atherosclerosis plaques via the Wnt1/β-catenin signalling pathway.Pharmaceutical biology · 2023Article
- Endothelial Cell Markers Are Inferior to Vascular Smooth Muscle Cells Markers in Staining Vasa Vasorum and Are Non-Specific for Distinct Endothelial Cell Lineages in Clinical Samples.International journal of molecular sciences · 2023Article
- bFGF blockade reduces intraplaque angiogenesis and macrophage infiltration in atherosclerotic vein graft lesions in ApoE3*Leiden mice.Scientific reports · 2020Article
- Vasa vasorum inside out/outside in communication: a potential role in the patency of saphenous vein coronary artery bypass grafts.Journal of cell communication and signaling · 2018Review
- Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.Clinical journal of the American Society of Nephrology : CJASN · 2018Observational
- Article
- Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease.Frontiers in immunology · 2018Review
- Integrin signaling in atherosclerosis.Cellular and molecular life sciences : CMLS · 2017Review
- The molecular basis of endothelial cell plasticity.Nature communications · 2017Review
- Nox and Inflammation in the Vascular Adventitia.Hypertension (Dallas, Tex. : 1979) · 2016Review
- Vasa vasorum in atherosclerosis and clinical significance.International journal of molecular sciences · 2015Review
- Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Anti-angiogenic activity of rPAI-1(23) and vasa vasorum regression.Trends in cardiovascular medicine · 2013Review
- Transforming growth factor-beta (TGF-β) in the pathogenesis of hereditary thoracic aneurysm disorders.Cardiovascular pathology : the official journal of the Society for Cardiovascular PathologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveVasa vasorum are angiogenic in advanced stages of human atherosclerosis and hypercholesterolemic mouse models. Fibroblast growth factor-2 (FGF-2) is the predominant angiogenic growth factor in the adventitia and plaque of hypercholesterolemic low-density lipoprotein receptor-deficient/apolipoprotein B(100/100) mice (DKO). FGF-2 seems to play a role in the formation of a distinct vasa vasorum network. This study examined the vasa vasorum structure and its relationship to FGF-2. METHODS AND
resultsDKO mice treated with saline, antiangiogenic recombinant plasminogen activator inhibitor-1(23) (rPAI-1(23)), or soluble FGF receptor 1 were perfused with fluorescein-labeled Lycopersicon esculentum lectin. Confocal images of FGF-2-probed descending aorta adventitia show that angiogenic vasa vasorum form a plexus-like network in saline-treated DKO similar to the FGF-2 pattern of distribution. Mice treated with rPAI-1(23) and soluble FGF receptor 1 lack a plexus; FGF-2 and vasa vasorum density and area are significantly reduced. A perlecan/FGF-2 complex is critical for plexus stability. Excess plasmin produced in rPAI-1(23)-treated DKO mice degrades perlecan and destabilizes the plexus. Plasmin activity and plaque size measured in DKO and DKO/plasminogen activator inhibitor-1(-)(/-) mice demonstrate that elevated plasmin activity contributes to reduced plaque size.
conclusionsAn FGF-2/perlecan complex is required for vasa vasorum plexus stability. Elevated plasmin activity plays a significant inhibitory role in vasa vasorum plexus and plaque development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.